While Mylan ( MYL) has consistently made headlines for controversy over the pricing of its EpiPen, an auto-injector used to treat anaphylaxis and severe food allergies, there's more to the pricing of its competitor than meets the eye. Released today, Kaleo's Auvi-Q will cost insurers 9 times more than the Epipen. In response, Express Scripts ( ESRX) , UnitedHealth Group ( UNH) and Cigna ( CI) will not cover the device.

This article was written by a staff member of TheStreet.

If you liked this article you might like

UPS's Long-Tenured Board Members Are a Red Flag for Investors

UPS's Long-Tenured Board Members Are a Red Flag for Investors

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget